Exercise for triple-negative breast cancer patients
Part of Cancer, Skin clinical trials.
This trial tests whether a structured exercise program can help women with newly diagnosed triple-negative breast cancer who are getting a specific combination of immunotherapy and chemotherapy. The goal is to see if staying active during treatment improves outcomes and well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old.
- You have been newly diagnosed with triple-negative breast cancer (stages I to III).
- You are scheduled to receive a treatment that includes both immunotherapy (pembrolizumab) and a type of chemotherapy called anthracycline-based.
- You do not have an unstable heart condition (like worsening coronary artery disease, heart failure, or dangerous heart rhythm problems).
- You do not have any bone or joint problem that would prevent you from exercising.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an exercise program can help women with triple-negative breast cancer during their chemotherapy treatment. You will be asked to participate in a supervised exercise routine while receiving your standard cancer drugs.
This study tests if aerobic exercise can help women and men with stage 2 or 3 triple-negative breast cancer who are getting chemotherapy and immunotherapy before surgery. It aims to see if exercise improves treatment outcomes and quality of life.
This trial looks at whether a structured physical exercise program during neoadjuvant chemotherapy can help women with triple-negative breast cancer. You may qualify if you are treated at the specific hospital in Madrid and your tumor matches the required type and size.
This study looks at whether a program of healthy eating and exercise, started during chemotherapy, can help shrink your tumor more effectively. You will be randomly assigned to either follow the diet and exercise plan or stick with your usual care.
This trial is testing whether a shorter course of chemo plus an immunotherapy drug called pembrolizumab works as well as the standard longer treatment for early-stage triple-negative breast cancer. The goal is to reduce side effects while keeping the treatment effective.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Cancer, Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.